AR010752A1 - COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN. - Google Patents

COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN.

Info

Publication number
AR010752A1
AR010752A1 ARP970105779A ARP970105779A AR010752A1 AR 010752 A1 AR010752 A1 AR 010752A1 AR P970105779 A ARP970105779 A AR P970105779A AR P970105779 A ARP970105779 A AR P970105779A AR 010752 A1 AR010752 A1 AR 010752A1
Authority
AR
Argentina
Prior art keywords
compounds
bind
activate
receptor
thrombopoyetine
Prior art date
Application number
ARP970105779A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR010752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR010752A1 publication Critical patent/AR010752A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP970105779A 1996-12-11 1997-12-09 COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN. AR010752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor

Publications (1)

Publication Number Publication Date
AR010752A1 true AR010752A1 (es) 2000-07-12

Family

ID=25071323

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970105779A AR010752A1 (es) 1996-12-11 1997-12-09 COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN.
ARP070104172A AR062931A2 (es) 1996-12-11 2007-09-20 Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070104172A AR062931A2 (es) 1996-12-11 2007-09-20 Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos

Country Status (24)

Country Link
US (2) US5869451A (enExample)
EP (3) EP2336165A1 (enExample)
JP (1) JP4128225B2 (enExample)
KR (3) KR100625708B1 (enExample)
CN (1) CN100379760C (enExample)
AR (2) AR010752A1 (enExample)
AT (1) ATE420893T1 (enExample)
AU (1) AU725731B2 (enExample)
BR (1) BRPI9713914B1 (enExample)
CA (1) CA2274149C (enExample)
CO (1) CO5080768A1 (enExample)
DE (1) DE69739219D1 (enExample)
ES (1) ES2321038T3 (enExample)
HR (1) HRP970683B1 (enExample)
MA (1) MA26454A1 (enExample)
PA (1) PA8442601A1 (enExample)
PE (1) PE27599A1 (enExample)
SV (1) SV1997000104A (enExample)
TN (1) TNSN97201A1 (enExample)
TR (2) TR200401638T2 (enExample)
TW (1) TW515804B (enExample)
UY (1) UY24805A1 (enExample)
WO (1) WO1998025965A2 (enExample)
ZA (1) ZA9711045B (enExample)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
JP3059218B2 (ja) * 1995-06-07 2000-07-04 グラクソ・グループ・リミテッド トロンボポエチン受容体に結合するペプチドおよび化合物
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US6280959B1 (en) 1997-10-31 2001-08-28 Smithkline Beecham Corporation Metal complexes
CA2308135A1 (en) * 1997-10-31 1999-05-14 John G. Gleason Novel metal complexes
AU748063B2 (en) 1997-10-31 2002-05-30 Ligand Pharmaceuticals Incorporated Novel metal complexes
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
SK287737B6 (sk) 1998-10-23 2011-08-04 Kirin-Amgen Inc. Peptidová zlúčenina, spôsob jej výroby a použitie, farmaceutický prostriedok, polynukleotid, vektor a hostiteľská bunka
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
US20030190644A1 (en) 1999-10-13 2003-10-09 Andreas Braun Methods for generating databases and databases for identifying polymorphic genetic markers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001036604A2 (en) 1999-11-18 2001-05-25 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
CA2407956A1 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ES2316919T3 (es) * 2000-12-05 2009-04-16 Alexion Pharmaceuticals, Inc. Anticuerpos diseñados racionalmente.
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7172892B2 (en) 2001-03-22 2007-02-06 Dendreon Corporation Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
NZ527971A (en) 2001-03-27 2006-03-31 Dendreon Corp Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1501863A4 (en) 2002-05-03 2007-01-24 Sequenom Inc KINASE ANCHOR PROTEIN, PEPTIDES AND RELATED METHODS THEREOF
WO2003097834A2 (en) 2002-05-17 2003-11-27 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
CA2448513A1 (en) * 2002-06-29 2003-12-29 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavone concentrates, as well as methods for their production
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
AU2003255030A1 (en) 2002-08-14 2004-03-03 Nissan Chemical Industries, Ltd. Thrombopoetin receptor activator and process for producing the same
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8067367B2 (en) * 2002-09-18 2011-11-29 Janssen Pharmaceutica, N.V. Methods of increasing platelet and hematopoietic stem cell production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
WO2004073624A2 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive methods and compositions related to proteasomal interference
BRPI0411160A (pt) 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
MXPA05012316A (es) * 2003-05-12 2006-04-18 Affymax Inc Peptidos novedosos que se unen al receptor de la eritropoyetina.
BRPI0411172A (pt) * 2003-05-12 2006-07-18 Affymax Inc peptìdeo, dìmero de peptìdeo, seu uso e composição farmacêutica
EP1628686A2 (en) 2003-05-12 2006-03-01 Affymax, Inc. Spacer moiety for poly (ethylene glycol)-modified peptides
CN103130739B (zh) * 2003-08-12 2015-09-16 盐野义制药株式会社 具有血小板生成素受体激动作用的化合物
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
ME00313B (me) * 2003-08-28 2011-05-10 Ortho Mcneil Pharm Inc Peptidi i jedinjenja koja se vežu za receptor
EP1701969B1 (en) 2003-12-31 2007-10-24 F.Hoffmann-La Roche Ag Process for peptide synthesis using a reduced amount of deprotection agent
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
EP1725576B1 (en) * 2004-02-20 2010-09-22 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
MX2007000216A (es) * 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
CN101103045B (zh) * 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
EP1814910A4 (en) * 2004-11-11 2009-04-29 Affymax Inc NEW AT ERYTHROPOIETIN RECEPTOR BINDING PEPTIDES
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
AU2005312585B2 (en) 2004-12-08 2012-01-12 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
KR101215207B1 (ko) 2004-12-14 2012-12-26 닛산 가가쿠 고교 가부시키 가이샤 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제
EP1861417B1 (en) 2005-03-10 2013-05-15 BioNTech AG Dimeric or multimeric microproteins
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP2008546732A (ja) * 2005-06-23 2008-12-25 アプラゲン ゲーエムベーハー 多価化合物
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8026368B2 (en) 2005-11-07 2011-09-27 Nissan Chemical Industries, Ltd. Hydrazide compounds and thrombopoietin receptor activators
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
AU2007208226A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
JP2009529917A (ja) 2006-03-22 2009-08-27 ヴァイラル ロジック システムズ テクノロジー コーポレーション 標的ポリペプチドの同定方法および免疫学的疾患の治療のためのその使用
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
JP2009537145A (ja) * 2006-05-15 2009-10-29 バイラル ロジック システムズ テクノロジー コーポレーション 免疫学的疾患および障害を治療するためのｃｄ４７と関連した組成物および方法
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2007150053A2 (en) * 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
US20090252703A1 (en) * 2006-10-19 2009-10-08 Gegg Jr Colin V Use of alcohol co-solvents to improve pegylation reaction yields
WO2008095004A2 (en) * 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
JP5591691B2 (ja) * 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
JP5701064B2 (ja) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド フェロポーチン抗体およびその使用方法
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
WO2011049213A1 (ja) 2009-10-23 2011-04-28 日産化学工業株式会社 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
US8993727B2 (en) 2010-09-22 2015-03-31 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
KR102330652B1 (ko) 2014-09-11 2021-11-23 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 및 cd80 (b7-1)/pd-li 단백질/단백질 상호작용의 마크로시클릭 억제제
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
BR112017010268B1 (pt) 2014-11-19 2024-01-16 P & M Venge Ab Agente de ligação, composição de diagnóstico, kit de diagnóstico, método de diagnóstico de uma infecção bacteriana ou de diferenciação entre uma infecção bacteriana e uma infecção de viral, métodos para descartar uma infecção bacteriana ou viral em um indivíduo, métodos para considerar uma infecção bacteriana ou viral em um indivíduo, método para distinguir entre uma infecção bacteriana ou mista e uma infecção viral em um indivíduo, método para descartar uma doença infecciosa, método para identificação do tipo de infecção e dispositivo para o diagnóstico de infecções bacterianas
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
ES2864091T3 (es) 2016-05-19 2021-10-13 Bristol Myers Squibb Co Inmunomoduladores de producción de imágenes de tomografía por emisión de positrones (PET)
JP7085545B2 (ja) 2016-11-07 2022-06-16 ブリストル－マイヤーズ スクイブ カンパニー 免疫修飾因子
EP3642220A1 (en) 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
CA3070442A1 (en) * 2017-07-26 2019-01-31 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
US11492375B2 (en) 2017-10-03 2022-11-08 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
WO2020154637A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
CA3127378A1 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
WO2020154585A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
US12403174B2 (en) 2020-01-06 2025-09-02 Bristol-Myers Squibb Company Immunomodulators
ES2970547T3 (es) 2020-03-30 2024-05-29 Bristol Myers Squibb Co Inmunomoduladores
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3645090A (en) 1969-06-19 1972-02-29 Citizen Watch Co Ltd Day-date quick-adjuster for calender timepiece
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) * 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0644771B2 (en) * 1992-06-11 2006-12-06 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU685506B2 (en) 1993-08-25 1998-01-22 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
WO1995011922A1 (en) * 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
FI963185L (fi) * 1994-02-14 1996-08-14 Zymogenetics Inc Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0723456A1 (en) * 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
SG79882A1 (en) * 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
WO1995026746A1 (en) * 1994-03-31 1995-10-12 Amgen Inc. Compositions and methods for stimulating megakaryocyte growth and differentiation
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1996017062A1 (en) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
ES2276401T3 (es) * 1995-04-26 2007-06-16 Kyowa Hakko Kogyo Co., Ltd. Proteinas de fusion g-csf tpo.
JP3059218B2 (ja) 1995-06-07 2000-07-04 グラクソ・グループ・リミテッド トロンボポエチン受容体に結合するペプチドおよび化合物
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체

Also Published As

Publication number Publication date
EP2336165A1 (en) 2011-06-22
KR100679576B1 (ko) 2007-02-07
EP0948539A2 (en) 1999-10-13
DE69739219D1 (de) 2009-03-05
JP2001505898A (ja) 2001-05-08
JP4128225B2 (ja) 2008-07-30
TW515804B (en) 2003-01-01
SV1997000104A (es) 1998-09-18
KR20060025611A (ko) 2006-03-21
TNSN97201A1 (fr) 2005-03-15
AU5854798A (en) 1998-07-03
EP2028191A1 (en) 2009-02-25
CA2274149A1 (en) 1998-06-18
KR20000069408A (ko) 2000-11-25
KR100668546B1 (ko) 2007-01-16
PA8442601A1 (es) 2000-05-24
ES2321038T3 (es) 2009-06-01
CA2274149C (en) 2008-07-15
WO1998025965A3 (en) 1998-08-13
AR062931A2 (es) 2008-12-17
PE27599A1 (es) 1999-03-29
AU725731B2 (en) 2000-10-19
HRP970683A2 (en) 1998-10-31
WO1998025965A2 (en) 1998-06-18
CN100379760C (zh) 2008-04-09
KR20050042505A (ko) 2005-05-09
BR9713914A (pt) 2000-02-29
CO5080768A1 (es) 2001-09-25
BRPI9713914B8 (enExample) 2021-05-25
ZA9711045B (en) 1999-06-09
ATE420893T1 (de) 2009-01-15
CN1245504A (zh) 2000-02-23
TR199901971T2 (xx) 1999-12-21
BRPI9713914B1 (pt) 2017-06-20
US5869451A (en) 1999-02-09
TR200401638T2 (tr) 2004-11-22
UY24805A1 (es) 2000-12-29
EP0948539B1 (en) 2009-01-14
US6121238A (en) 2000-09-19
HRP970683B1 (en) 2002-10-31
KR100625708B1 (ko) 2006-09-20
MA26454A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
AR010752A1 (es) COMPUESTOS QUE SE ENLAZAN A Y ACTIVAN UN RECEPTOR DE LA TROMBOPOYETINA; COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, SU USO PARA LA PREPARACION DE MEDICAMENTOS, Y PROCESO PARA PREPARAR DICHA COMPOSICIoN.
AR003431A1 (es) Peptidos compuestos que se ligan al receptor de trombopoietina.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
ES2058139T3 (es) Compuestos complejos de bioflavonoides con fosfolipidos, su preparacion y uso, y composiciones farmaceuticas y cosmeticas que los contienen.
AR003427A1 (es) Péptidos relacionados con dolastatina, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y el uso de los mismos para la preparación de dichas composiciones farmacéuticas.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
AR011539A1 (es) DERIVADOS DE BENZOILO-3-HETEROCICLIL-SUSTITUIDOS, PROCEDIMIENTO PARA SU PREPARACIoN,COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHO PROCEDIMIENTO, COMPOSICIONES QUE COMPRENDEN DICHOS DERIVADOS, Y PROCEDIMIENTO PARA SU PREPARACIoN, PROCEDIMIENTO PARA COMBATIR VEGETACIoN NO DESADA QUE LOS EMPLEA Y SU
MX9403570A (es) Conjugados de farmaco-ligando, proceso para su preparacion y composicionesfarmaceuticas que los incluyen.
ES2191187T3 (es) Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
AR023574A1 (es) Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
AR024516A1 (es) Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica.
BR0214137A (pt) Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos
CO5640082A2 (es) Compuestos derivados de succinimida heterociclicos fusionados que son moduladores de la funcion del receptor de la hormona nuclear y composiciones farmaceuticas que los contienen
BR9813378A (pt) Composto, processo para preparar o mesmo, e uso do mesmo, composição farmacêutica, e processo para a preparação da mesma, e, processo de efetuar a imunossupressão
YU34196A (sh) Peptidi i jedinjenja koja se vezuju za receptor
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
ES2153367T3 (es) Derivados de clorofila y de bacterioclorofila, su preparacion y composiciones farmaceuticas que los contienen.
UY23561A1 (es) Procedimiento para la preparacion de tnf-muteinas
EA199900734A1 (ru) Микрокапсулы, содержащие цис-платину
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
BR9608488A (pt) Uso de derivados da vitamina d4 no tratamento de câncer
GT199800106A (es) Azetidinas.
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FG Grant, registration